This week, the insurer rolled out some of the changes it will be implementing in its Medicare Advantage (MA) plans as of January 1, 2019.
When CMS announced in August 2018 its policy change to allow Medicare Advantage (MA) plans to utilize step therapy as a way to negotiate drug prices, UnitedHealthcare, the nation’s largest MA carrier, publicly celebrated the decision. This week, the insurer rolled out some of the changes it will be implementing in its MA plans as of January 1, 2019.
In a bulletin released this month, UnitedHealthcare stated that it will employ step therapy to control costs of biologics, such as reference infliximab, sold as Remicade. Now listed as preferred drugs on its MA plan, which requires the product to be used first before a patient moves to another therapy, are infliximab biosimilars, Inflectra and Renflexis.
In addition, UnitedHealthcare has also listed biosimilar epoetin alfa, sold as Retacrit, as a preferred drug; however, it noted that step therapy will not apply to this product, or to patients already taking epoetin.
UnitedHealthcare also wrote that biosimilar pegfilgrastim, sold as Fulphila, and biosimilar filgrastim, sold as Nivestym, will require prior authorization when administered to patients with cancer in an outpatient setting.
When CMS Administrator Seema Verma announced the change in policy for MA plans, she indicated that it was her hope for MA plans to begin treatment with a cost-effective biosimilar before progressing to a more expensive therapy if the treatment was ineffective. Notably, however, she did not specify whether patients would be switched to a biosimilars reference product, or whether patients would be required to begin treatment with a biosimilar of one therapy before being permitted to cycle to a different biologic treatment altogether.
Contrary to UnitedHealthcare welcoming this policy change, rheumatology and oncology providers have expressed concern over the move, as step therapy, often referred to by critics as “fail-first,” can be harmful to patients with chronic conditions.
When speaking about step therapy proposals as a whole, the American College of Rheumatology (ACR) president, David Daikh, MD, PhD, said “While we support the goal of decreasing the cost of medications, the ACR has long opposed step therapy and other utilization management techniques that undermine the clinical judgement of providers, delay access to needed treatments, and put our patients’ health at unnecessary risk.”
Echoing this concern, The Community Oncology Alliance president called the change the “antithesis of where personalized cancer treatment is going,” and spoke out against the “one-size-fits-all” approach of treatment.
As of now, UnitedHealthcare is the only major insurer to publicly announce employing step therapy in its MA plans for 2019. In an email to The American Journal of Managed Care®, a sister site of The Center for Biosimilars®, a representative from Aetna explained that it is still evaluating whether or not to employ step therapy, and a representative from Kaiser Permanente confirmed that it will not be utilizing step therapy in 2019, but is evaluating making the change in 2020.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.